Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Ambry Genetics, a leader in clinical genomic ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genetic and genomic testing, today announced enhancements to their portfolio of tests for the detection of genetic mutations ...

Direct-to-consumer gene tests like Ancestry.com and 23andMe are increasingly informing consumers about gene alterations that could signal health risks. But those tests look at only a few positions on ...

Peer-reviewed study in the Journal of the National Comprehensive Cancer Network describes the CARE program’s utility as digital risk assessment tool validated with real-world patient data ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Tempus AI announced today it is acquiring genetic testing ...

LEXINGTON, KY, UNITED STATES, March 11, 2026 /EINPresswire.com/ — The Child Neurology Foundation (CNF) today announced Ambry Genetics, now a wholly owned subsidiary ...

Orange County’s third largest medical diagnostics and testing company is being acquired by a fast-growing Chicago-based firm using artificial intelligence for precision medicine. Aliso Viejo-based ...

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics first implemented RNA testing in 2016 as part of a research and ...

Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the completion of its one-millionth DNA/RNA test, underscoring the ...